Abstract:Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic steatohepatitis (NASH) comprise a spectrum of chronic liver diseases in the global population that can lead to end-stage liver disease and hepatocellular carcinoma (HCC). NAFLD is closely linked to the metabolic syndrome, and comorbidities such as type 2 diabetes, obesity and insulin resistance aggravate liver disease, while NAFLD promotes cardiovascular risk in affected patients. The pathomechanisms of NAFLD are multifaceted, combining hepatic factors including lipotoxicity, mechanisms of cell death and liver inflammation with extrahepatic factors including metabolic disturbance and dysbiosis. Nuclear receptors (NRs) are a family of ligand-controlled transcription factors that regulate glucose, fat and cholesterol homeostasis and modulate innate immune cell functions, including liver macrophages. In parallel with metabolic derangement in NAFLD, altered NR signaling is frequently observed and might be involved in the pathogenesis. Therapeutically, clinical data indicate that single drug targets thus far have been insufficient for reaching patient-relevant endpoints. Therefore, combinatorial treatment strategies with multiple drug targets or drugs with multiple mechanisms of actions could possibly bring advantages, by providing a more holistic therapeutic approach. In this context, peroxisome proliferator-activated receptors (PPARs) and other NRs are of great interest as they are involved in wide-ranging and multi-organ activities associated with NASH progression or regression. In this review, we summarize recent advances in understanding the pathogenesis of NAFLD, focusing on mechanisms of cell death, immunometabolism and the role of NRs. We outline novel therapeutic strategies and discuss remaining challenges.

Nuclear receptor-mediated hepatomegaly and liver regeneration: an update

Nuclear Receptors and Non-Alcoholic Fatty Liver Disease: an Update

Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease

Essential Role of Nuclear Receptors for the Evaluation of the Benefits of Bioactive Herbal Extracts on Liver Function

Bile Acid Signaling and Liver Regeneration.

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

Nuclear receptors in renal health and disease

MicroRNAs in Liver Regeneration

Nuclear Receptors and Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease

Hormonal Contribution to Liver Regeneration

Distinct Role of Nuclear Receptor Corepressor 1 Regulated De Novo Fatty Acids Synthesis in Liver Regeneration and Hepatocarcinogenesis in Mice

Targeting NR1D1 in organ injury: challenges and prospects

Structural Overview and Perspectives of the Nuclear Receptors, a Major Family As the Direct Targets Forsmall-Molecule Drugs

Neuregulin 4 Suppresses NASH-HCC Development by Restraining Tumor-Prone Liver Microenvironment

Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease

Nuclear Receptor Variants in Liver Disease

Adenovirus-mediated expression of orphan nuclear receptor NR4A2 targeting hepatic stellate cell attenuates liver fibrosis in rats

The Nuclear Orphan Receptor NR2F6 Promotes Hepatic Steatosis through Upregulation of Fatty Acid Transporter CD36

Metabolic nuclear receptors coordinate energy metabolism to regulate Sox9+ hepatocyte fate

Roles and mechanisms of NRG1 in modulating the pathogenesis of NAFLD through ErbB3 signaling in hepatocytes (NRG1 modulates NAFLD through ErbB3 signaling)

Orphan Nuclear Receptor NR4A2 Inhibits Hepatic Stellate Cell Proliferation Through MAPK Pathway in Liver Fibrosis